Unknown

Dataset Information

0

Botulinum Toxin Use in Neurourology.


ABSTRACT: The use of botulinum toxin A (BTX-A) has revolutionized the treatment of neurogenic lower urinary tract dysfunction (NLUTD) over the past three decades. Initially, it was used as a sphincteric injection for detrusor sphincter dyssynergia but now is used mostly as intradetrusor injection to treat neurogenic detrusor overactivity (NDO). Its use is supported by high-level-of-evidence studies and it has become the gold-standard treatment for patients with NDO refractory to anticholinergics. Several novelties have emerged in the use of BTX-A in neurourology over the past few years. Although onabotulinumtoxinA (BOTOX®, Allergan, Inc., Irvine, CA) remains the only BTX-A for which use is supported by large, multicenter, randomized, controlled trials (RCT), and is therefore the only one to be licensed in the United States and Europe, a second BTX-A, abobotulinumtoxinA (Dysport®, Ipsen Biopharmaceuticals, Basking Ridge, NJ), is also supported by high-level-of-evidence studies. Other innovations in the use of BTX-A in neurourology during the past few years include the BTX switch (from abobotulinumtoxinA to onabotulinumtoxinA or the opposite) as a rescue option for primary or secondary failures of intradetrusor BTX-A injection and refinements in intradetrusor injection techniques (number of injection sites, injection into the trigone). There is also a growing interest in long-term failure of BTX-A for NDO and their management, and a possible new indication for urethral sphincter injections.

SUBMITTER: Peyronnet B 

PROVIDER: S-EPMC6168325 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Botulinum Toxin Use in Neurourology.

Peyronnet Benoit B   Gamé Xavier X   Vurture Gregory G   Nitti Victor W VW   Brucker Benjamin M BM  

Reviews in urology 20180101 2


The use of botulinum toxin A (BTX-A) has revolutionized the treatment of neurogenic lower urinary tract dysfunction (NLUTD) over the past three decades. Initially, it was used as a sphincteric injection for detrusor sphincter dyssynergia but now is used mostly as intradetrusor injection to treat neurogenic detrusor overactivity (NDO). Its use is supported by high-level-of-evidence studies and it has become the gold-standard treatment for patients with NDO refractory to anticholinergics. Several  ...[more]

Similar Datasets

| S-EPMC6586173 | biostudies-literature
| S-EPMC4241086 | biostudies-other
| S-EPMC3070188 | biostudies-literature
| S-EPMC10142089 | biostudies-literature
| S-EPMC6464099 | biostudies-literature
| S-EPMC6353364 | biostudies-literature
| S-EPMC7291335 | biostudies-literature
| S-EPMC8683856 | biostudies-literature
| S-EPMC6115806 | biostudies-other
| S-EPMC5705980 | biostudies-other